Mumps and Other Types of Viral Parotitis

  • Sigrid Gouma
  • Marlene L. Durand
  • Rob S. van BinnendijkEmail author


Mumps is the most common cause of epidemic parotitis. Although vaccination has greatly reduced the incidence and morbidity of mumps, outbreaks have occurred frequently among vaccinated populations over the past two decades. Unlike outbreaks in the pre-vaccine era, which primarily affected children, recent outbreaks have predominantly affected young adults. The diagnosis of mumps relies on clinical features and laboratory findings, and is usually not difficult in unvaccinated patients. However, laboratory diagnosis in vaccinated patients is challenging due to the limited value of serologic studies and the brief window of time during which the virus can be detected in oral specimens. This chapter reviews the clinical and laboratory features of mumps as well as other viral etiologies of parotitis, including influenza virus, adenovirus, Epstein-Barr virus, parainfluenza virus, and enterovirus.


Mumps Mumps vaccination Parotitis Viral parotitis 


  1. 1.
    Tsoucalas G, Laios K, Karamanou M, Androutsos G. The Thasian epidemic 5th century BC. Infez Med. 2013;21(2):149–50.PubMedGoogle Scholar
  2. 2.
    Johnson CD, Goodpasture EW. An investigation of the etiology of mumps. J Exp Med. 1934;59(1):1–19.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Johnson CD, Goodpasture EW. The etiology of mumps. Am J Hyg. 1935;21:46–57.Google Scholar
  4. 4.
    Rubin SA, Sauder CJ, Carbone KM. Mumps virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2013. p. 1024–41.Google Scholar
  5. 5.
    Gupta RK, Best J, MacMahon E. Mumps and the UK epidemic 2005. BMJ. 2005;330(7500):1132–5.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Centers for Disease Control and Prevention. Mumps cases and outbreaks. Atlanta, GA: Centers for Disease Control and Prevention; 2018.Google Scholar
  7. 7.
    Galazka AM, Robertson SE, Kraigher A. Mumps and mumps vaccine: a global review. Bull World Health Organ. 1999;77(1):3–14.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Edmunds WJ, Gay NJ, Kretzschmar M, Pebody RG, Wachmann H. The pre-vaccination epidemiology of measles, mumps and rubella in Europe: implications for modelling studies. Epidemiol Infect. 2000;125(3):635–50.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Wagenvoort JH, Harmsen M, Boutahar-Trouw BJ, Kraaijeveld CA, Winkler KC. Epidemiology of mumps in the Netherlands. J Hyg (Lond). 1980;85(3):313–26.CrossRefGoogle Scholar
  10. 10.
    Morgan-Capner P, Wright J, Miller CL, Miller E. Surveillance of antibody to measles, mumps, and rubella by age. BMJ. 1988;297(6651):770–2.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Janaszek-Seydlitz W, Bucholc B, Gorska P, Slusarczyk J. Mumps in Poland since 1990 to 2003; epidemiology and antibody prevalence. Vaccine. 2005;23(21):2711–6.PubMedCrossRefGoogle Scholar
  12. 12.
    World Health Organization. Mumps virus vaccines. Wkly Epidemiol Rec. 2007;82(7):51–60.Google Scholar
  13. 13.
    CDC. Brief report: update: mumps activity – United States, January 1–October 7, 2006. MMWR Morb Mortal Wkly Rep. 2006;55(42):1152–3.Google Scholar
  14. 14.
    Castilla J, Garcia Cenoz M, Barricarte A, Irisarri F, Núñez-Córdoba J, Barricarte A. Mumps outbreak in Navarre region, Spain, 2006–2007. Euro Surveill. 2007;12(2):E070215.1.PubMedGoogle Scholar
  15. 15.
    Bangor-Jones RD, Dowse GK, Giele CM, Van Buynder PG, Hodge MM, Whitty MM. A prolonged mumps outbreak among highly vaccinated aboriginal people in the Kimberley region of Western Australia. Med J Aust. 2009;191(7):398–401.PubMedGoogle Scholar
  16. 16.
    Otto W, Mankertz A, Santibanez S, Saygili H, Wenzel J, Jilg W, et al. Ongoing outbreak of mumps affecting adolescents and young adults in Bavaria, Germany, August to October 2010. Eur Secur. 2010;15(50):19748.Google Scholar
  17. 17.
    Anis E, Grotto I, Moerman L, Warshavsky B, Slater PE, Lev B. Mumps outbreak in Israel’s highly vaccinated society: are two doses enough? Epidemiol Infect. 2012;140(3):439–46.PubMedCrossRefGoogle Scholar
  18. 18.
    Braeye T, Linina I, De Roy R, Hutse V, Wauters M, Cox P, et al. Mumps increase in Flanders, Belgium, 2012-2013: results from temporary mandatory notification and a cohort study among university students. Vaccine. 2014;32(35):4393–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Whelan J, van Binnendijk R, Greenland K, Fanoy E, Khargi M, Yap K, et al. Ongoing mumps outbreak in a student population with high vaccination coverage, Netherlands, 2010. Eur Secur. 2010;15(17):11–4.Google Scholar
  20. 20.
    Deeks SL, Lim GH, Simpson MA, Gagné L, Gubbay J, Kristjanson E, et al. An assessment of mumps vaccine effectiveness by dose during an outbreak in Canada. CMAJ. 2011;183(9):1014–20.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    World Health Organization. Mumps virus nomenclature update: 2012. Wkly Epidemiol Rec. 2012;87:217–24.Google Scholar
  22. 22.
    Cortese MM, Barskey AE, Tegtmeier GE, Zhang C, Ngo L, Kyaw MH, et al. Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity. J Infect Dis. 2011;204(9):1413–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Rubin SA, Qi L, Audet SA, Sullivan B, Carbone KM, Bellini WJ, et al. Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak. J Infect Dis. 2008;198(4):508–15.PubMedCrossRefGoogle Scholar
  24. 24.
    Gouma S, ten Hulscher H, Schurink-van ‘t Klooster TM, de Melker HE, Boland GJ, Kaaijk P, et al. Mumps-specific cross-neutralization by MMR vaccine-induced antibodies predicts protection against mumps virus infection. Vaccine. 2016;34(35):4166–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Greenland K, Whelan J, Fanoy E, Borgert M, Hulshof K, Yap KB, et al. Mumps outbreak among vaccinated university students associated with a large party, the Netherlands, 2010. Vaccine. 2012;30(31):4676–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Anderson LJ, Seward JF. Mumps epidemiology and immunity: the anatomy of a modern epidemic. Pediatr Infect Dis J. 2008;27(10 Suppl):S75–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Jick H, Chamberlin DP, Hagberg KW. The origin and spread of a mumps epidemic. Epidemiology. 2009;20(5):656–61.PubMedCrossRefGoogle Scholar
  28. 28.
    Huang AS, Cortese MM, Curns AT, Bitsko RH, Jordan HT, Soud F, et al. Risk factors for mumps at a university with a large mumps outbreak. Public Health Rep. 2009;124(3):419–26.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Gouma S, Schurink-van ‘t Klooster TM, de Melker HE, Kerkhof J, Smits GP, SJM H, et al. Mumps serum antibody levels before and after an outbreak to assess infection and immunity in vaccinated students. Open Forum Infect Dis. 2014;1(3):ofu101.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Centers for Disease Control and Prevention. Mumps. Atlanta, GA: Centers for Disease Control and Prevention; 2017.Google Scholar
  31. 31.
    Ennis F, Jackson D. Isolation of virus during the incubation period of mumps infection. J Pediatr. 1968;72(4):536–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Tan KE, Anderson M, Krajden M, Petric M, Mak A, Naus M. Mumps virus detection during an outbreak in a highly vaccinated population in British Columbia. Can J Pub Heal. 2011;102(1):47–50.Google Scholar
  33. 33.
    Centers for Disease Control and Prevention. Updated recommendations for isolation of persons with mumps. MMWR Morb Mortal Wkly Rep. 2008;57(40):1103–5.Google Scholar
  34. 34.
    Philip RN, Reinhard KR, Lackman DB. Observations on a mumps epidemic in a “virgin” population. 1958. Am J Epidemiol. 1995;142(3):233–53.PubMedCrossRefGoogle Scholar
  35. 35.
    Rota JS, Rosen JB, Doll MK, McNall RJ, McGrew M, Williams N, et al. Comparison of the sensitivity of laboratory diagnostic methods from a well-characterized outbreak of mumps in New York City in 2009. Clin Vaccine Immunol. 2013;20(3):391–6.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Zamir CS, Schroeder H, Shoob H, Abramson N, Zentner G. Characteristics of a large mumps outbreak: clinical severity, complications and association with vaccination status of mumps outbreak cases. Hum Vaccin Immunother. 2015;11(6):1413–7.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Hviid A, Rubin S, Mühlemann K. Mumps. Lancet. 2008;371:932–44.PubMedCrossRefGoogle Scholar
  38. 38.
    Dittrich S, Hahné S, van Lier A, Kohl R, Boot H, Koopmans M, et al. Assessment of serological evidence for mumps virus infection in vaccinated children. Vaccine. 2011;29(49):9271–5.PubMedCrossRefGoogle Scholar
  39. 39.
    Tae BS, Ham BK, Kim JH, Park JY, Bae JH. Clinical features of mumps orchitis in vaccinated postpubertal males: a single-center series of 62 patients. Korean J Urol. 2012;53(12):865–9.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Masarani M, Wazait H, Dinneen M. Mumps orchitis. J R Soc Med. 2006;99(11):573–5.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Bjorvatn B. Mumps virus recovered from testicles by fine-needle aspiration biopsy in cases of human orchitis. Scand J Infect Dis. 1973;5(1):3–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Jalal H, Bahadur G, Knowles W, Jin L, Brink N. Mumps epididymo-orchitis with prolonged detection of virus in semen and the development of anti-sperm antibodies. J Med Virol. 2004;73(1):147–50.PubMedCrossRefGoogle Scholar
  43. 43.
    Clifford V, Wadsley J, Jenner B, Buttery JP. Mumps vaccine associated orchitis: evidence supporting a potential immune-mediated mechanism. Vaccine. 2010;28(14):2671–3.PubMedCrossRefGoogle Scholar
  44. 44.
    Yung CF, Andrews N, Bukasa A, Brown KE, Ramsay M. Mumps complications and effects of mumps vaccination, England and Wales, 2002–2006. Emerg Infect Dis. 2011;17(4):661–7.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Orlíková H, Malý M, Lexová P, Šebestová H, Limberková R, Jurzykowská L, et al. Protective effect of vaccination against mumps complications, Czech Republic, 2007–2012. BMC Public Health. 2016;16(1):293.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Hahné S, Whelan J, van Binnendijk R, Swaan C, Fanoy E, Boot H, et al. Mumps vaccine effectiveness against orchitis. Emerg Infect Dis. 2012;18(1):191–3.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Barskey AE, Schulte C, Rosen JB, Handschur EF, Rausch-Phung E, Doll MK, et al. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med. 2012;367(18):1704–13.PubMedCrossRefGoogle Scholar
  48. 48.
    Sullivan KM, Halpin TJ, Kim-Farley R, Marks JS. Mumps disease ands its health impact: an outbreak based report. Pediatrics. 1985;76(4):533–6.PubMedGoogle Scholar
  49. 49.
    Falk WA, Buchan K, Dow M, Garson JZ, Hill E, Nosal M, et al. The epidemiology of mumps in southern Alberta 1980–1982. Am J Epidemiol. 1989;130(4):736–49.PubMedCrossRefGoogle Scholar
  50. 50.
    Kabakus N, Aydinoglu H, Yekeler H, Arslan I. Fatal mumps nephritis and myocarditis. J Trop Pediatr. 1999;45(6):358–60.PubMedCrossRefGoogle Scholar
  51. 51.
    Gut JP, Lablache C, Behr S, Kirn A. Symptomatic mumps virus reinfections. J Med Virol. 1995;45(1):17–23.PubMedCrossRefGoogle Scholar
  52. 52.
    Centers for Disease Control and Prevention. Mumps 2012 case definition.
  53. 53.
    Centers for Disease Control and Prevention. Laboratory confonfirmation by IgM serology and questions and answers [Internet].
  54. 54.
    Krause I, Wu R, Sherer Y, Patanik M, Peter JB, Shoenfeld Y. In vitro antiviral and antibacterial activity of commercial intravenous immunoglobulin preparations—a potential role for adjuvant intravenous immunoglobulin therapy in infectious diseases. Transfus Med. 2002;12(2):133–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Suga K, Goji A, Shono M, Matsuura S, Inoue M, Toda E, et al. Mumps encephalitis with akinesia and mutism. Pediatr Int. 2015;57(4):721–4.PubMedCrossRefGoogle Scholar
  56. 56.
    Erpenbach K. Systemic treatment with interferon-alpha 2B: an effective method to prevent sterility after bilateral mumps orchitis. J Urol. 1991;146(1):54–6.PubMedCrossRefGoogle Scholar
  57. 57.
    Ku J, Kim Y, Jeon Y, Lee N. The preventive effect of systemic treatment with interferon-alpha2B for infertility from mumps orchitis. BJU Int. 1999;84(7):839–42.PubMedCrossRefGoogle Scholar
  58. 58.
    Yeniyol CO, Sorguc S, Minareci S, Ayder AR. Role of interferon-alpha-2B in prevention of testicular atrophy with unilateral mumps orchitis. Urology. 2000;55(6):931–3.PubMedCrossRefGoogle Scholar
  59. 59.
    Kaaijk P, van der Zeijst B, Boog M, Hoitink C. Increased mumps incidence in the Netherlands: review on the possible role of vaccine strain and genotype. Euro Surveill. 2008;13(26):pii: 18914.Google Scholar
  60. 60.
    Buynak E, Hilleman M. Live attenuated mumps virus vaccine. 1. Vaccine development. Proc Soc Exp Biol Med. 1966;123(3):768–75.PubMedCrossRefGoogle Scholar
  61. 61.
    Afzal MA, Pickford AR, Forsey T, Minor PD. Heterogeneous mumps vaccine. Lancet. 1992;340(8825):980–1.PubMedCrossRefGoogle Scholar
  62. 62.
    Afzal MA, Pickford AR, Forsey T, Heath AB, Minor PD. The Jeryl Lynn vaccine strain of mumps virus is a mixture of two distinct isolates. J Gen Virol. 1993;74(Pt 5):917–20.PubMedCrossRefGoogle Scholar
  63. 63.
    Chambers P, Rima BK, Duprex WP. Molecular differences between two Jeryl Lynn mumps virus vaccine component strains, JL5 and JL2. J Gen Virol. 2009;90(12):2973–81.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Marin M, Quinlisk P, Shimabukuro T, Sawhney C, Brown C, LeBaron CW. Mumps vaccination coverage and vaccine effectiveness in a large outbreak among college students-Iowa, 2006. Vaccine. 2008;26(29–30):3601–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, et al. Vaccine effectiveness estimates, 2004–2005 mumps outbreak. Engl Emerg Infect Dis. 2007;13(1):12–7.Google Scholar
  66. 66.
    Harling R, White JM, Ramsay ME, Macsween KF, van den Bosch C. The effectiveness of the mumps component of the MMR vaccine: a case control study. Vaccine. 2005;23(31):4070–4.PubMedCrossRefGoogle Scholar
  67. 67.
    Snijders BEP, van Lier A, van de Kassteele J, Fanoy EB, Ruijs WLM, Hulshof F, et al. Mumps vaccine effectiveness in primary schools and households, the Netherlands, 2008. Vaccine. 2012;30(19):2999–3002.PubMedCrossRefGoogle Scholar
  68. 68.
    Sartorius B, Penttinen P, Nilsson J, Johansen K, Jönsson K, Arneborn M, et al. An outbreak of mumps in Sweden, February–April 2004. Eur Secur. 2005;10(9):559.Google Scholar
  69. 69.
    Schaffzin JK, Pollock L, Schulte C, Henry K, Dayan G, Blog D, et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics. 2007;120(4):e862–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Livingston KA, Rosen JB, Zucker JR, Zimmerman CM. Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City. Vaccine. 2014;32(3):369–74.PubMedCrossRefGoogle Scholar
  71. 71.
    Hanna-Wakim R, Yasukawa LL, Sung P, Arvin AM, Gans HA. Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis. 2008;197(2):1669–75.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, Beeler J, et al. Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis. 2001;184(7):817–26.PubMedCrossRefGoogle Scholar
  73. 73.
    Jokinen S, Osterlund P, Julkunen I, Davidkin I. Cellular immunity to mumps virus in young adults 21 years after measles-mumps-rubella vaccination. J Infect Dis. 2007;196(6):861–7.PubMedCrossRefGoogle Scholar
  74. 74.
    Christenson B, Böttiger M. Methods for screening the naturally acquired and vaccine-induced immunity to the mumps virus. Biologicals. 1990;18(3):213–9.PubMedCrossRefGoogle Scholar
  75. 75.
    Smits G, Mollema L, Hahné S, de Melker H, Tcherniaeva I, Waaijenborg S, et al. Seroprevalence of mumps in the Netherlands: dynamics over a decade with high vaccination coverage and recent outbreaks. PLoS One. 2013;8(3):e58234.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR vaccine-induced protection. J Infect Dis. 2012;206(10):1542–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Davidkin I, Jokinen S, Paananen A, Leinikki P, Peltola H. Etiology of mumps-like illnesses in children and adolescents vaccinated for measles, mumps, and rubella. J Infect Dis. 2005;191(5):719–23.PubMedCrossRefGoogle Scholar
  78. 78.
    Barrabeig I, Costa J, Rovira A, Marcos MA, Isanta R, Cervilla A, et al. Viral etiology of mumps-like illnesses in suspected mumps cases reported in Catalonia, Spain. Hum Vaccin Immunother. 2014;11(1):282–7.PubMedPubMedCentralCrossRefGoogle Scholar
  79. 79.
    Barskey AE, Juieng P, Whitaker BL, Erdman DD, Oberste MS, Chern SWW, et al. Viruses detected among sporadic cases of parotitis, United States, 2009–2011. J Infect Dis. 2013;208(12):1979–86.PubMedCrossRefGoogle Scholar
  80. 80.
    Hatchette TF, Mahony JB, Chong S, LeBlanc JJ. Difficulty with mumps diagnosis: what is the contribution of mumps mimickers? J Clin Virol. 2009;46(4):381–3.PubMedCrossRefGoogle Scholar
  81. 81.
    Krilov L, Swenson P. Acute parotitis associated with influenza A infection. J Infect Dis. 1985;152(4):853.PubMedCrossRefGoogle Scholar
  82. 82.
    Liu WK, Liu Q, Chen DH, Liang HX, Chen XK, Huang WB, et al. Epidemiology and clinical presentation of the four human parainfluenza virus types. BMC Infect Dis. 2013;13:28.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Frost HM, Robinson CC, Dominguez SR. Epidemiology and clinical presentation of parainfluenza type 4 in children: a 3-year comparative study to parainfluenza types 1–3. J Infect Dis. 2014;209(5):695–702.PubMedCrossRefGoogle Scholar
  84. 84.
    Centers for Disease Control and Prevention. Centers for Disease Control and Prevention. 2016–2017 influenza update for health care providers: parotitis and influenza. Atlanta, GA: Centers for Disease Control and Prevention; 2016.Google Scholar
  85. 85.
    Yoshida M, Higuchi T. Herpes zoster ophthalmicus with ipsilateral parotitis. Int J Dermatol. 2013;52(6):769–70.PubMedCrossRefGoogle Scholar
  86. 86.
    Lewis JM, Utz JP. Orchitis, parotitis and meningoencephalitis due to lymphocytic-choriomeningitis virus. N Engl J Med. 1961;265:776–80.PubMedCrossRefGoogle Scholar
  87. 87.
    Wilson KF, Meier JD, Ward PD. Salivary gland disorders. Am Fam Physician. 2007;89(11):882–8.Google Scholar
  88. 88.
    Schiødt M. HIV-associated salivary gland disease: a review. Oral Surg Oral Med Oral Pathol. 1992;73(2):164–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Mandel L, Surattanont F. Bilateral parotid swelling: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(3):221–37.PubMedCrossRefGoogle Scholar
  90. 90.
    Jeffers L, Webster-Cyriaque JY. Viruses and salivary gland disease (SGD): lessons from HIV SGD. Adv Dent Res. 2011;23(1):79–83.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Shivhare P, Shankarnarayan L, Jambunath U, Malligene Basavarju S. Benign lymphoepithelial cysts of parotid and submandibular glands in a HIV-positive patient. J Oral Maxillofac Pathol. 2015;19:107.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Sujatha D, Babitha K, Prasad RS, Pai A. Parotid lymphoepithelial cysts in human immunodeficiency virus: a review. J Laryngol Otol. 2013;127:1046–9.PubMedCrossRefGoogle Scholar
  93. 93.
    Shanti RM, Aziz SR. HIV-associated salivary gland disease. Oral Maxillofac Surg Clin N Am. 2009;21:339–43.CrossRefGoogle Scholar
  94. 94.
    Dave SP, Pernas FG, Roy S. The benign lymphoepithelial cyst and a classification system for lyphocytic parotid gland enlargement in the pediatric HIV population. Laryngoscope. 2007;117:106–13.PubMedCrossRefGoogle Scholar
  95. 95.
    Syebele K, Butow KW. Comparative study of the effect of antiretroviral therapy on benign lymphoepithelial cyst of parotid glands and ranulas in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;111:205–10.PubMedCrossRefGoogle Scholar
  96. 96.
    Gelfand MS, Cleveland KO, Lancaster D, Corbett CE, Florendo NT. Adenovirus parotitis in patients with AIDS. Clin Infect Dis. 1994;19(6):1045–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Crumpacker II, Clyde S. Cytomegalovirus (CMV). In: Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Dougla, and Bennett’s principles and practice of infectious diseases. 8th ed. Philadelphia, PA: Elsevier (Saunders); 2015.Google Scholar
  98. 98.
    Greenberg MS, Glick M, Nghiem L, Stewart JC, Hodinka R, Dubin G. Relationship of cytomegalovirus to salivary gland dysfunction in HIV-infected patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83(3):334–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Carrozzo M, Gandolfo S. Oral diseases possibly associated with hepatitis C virus. Crit Rev Oral Biol Med. 2003;14(2):115–27.PubMedCrossRefGoogle Scholar
  100. 100.
    Carrozzo M, Scally K. Oral manifestations of hepatitis C virus infection. World J Gastroenterol. 2014;20(24):7534–43.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Grossmann SM, Teixeira R, Oliveira GC, Gleber-Netto FO, Araújo FM, Araújo FM, et al. Xerostomia, hyposalivation and sialadenitis in patients with chronic hepatitis C are not associated with the detection of HCV RNA in saliva or salivary glands. J Clin Pathol. 2010;63(11):1002–7.CrossRefGoogle Scholar
  102. 102.
    Schreiber A, Hershman G. Non-HIV viral infections of the salivary glands. Oral Maxillofac Surg Clin North Am. 2009;21(3):331–8.PubMedCrossRefGoogle Scholar
  103. 103.
    Croia C, Astorri E, Murray-Brown W, Willis A, Brokstad KA, Sutcliffe N, et al. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjögren’s syndrome. Arthritis Rheumatol. 2014;66(9):2545–57.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Sigrid Gouma
    • 1
  • Marlene L. Durand
    • 2
    • 3
  • Rob S. van Binnendijk
    • 4
    Email author
  1. 1.Department of MicrobiologyPerelman School of Medicine, University of PennsylvaniaPhiladelphiaUSA
  2. 2.Division of Infectious Diseases, Department of Medicine, Massachusetts General HospitalHarvard Medical SchoolBostonUSA
  3. 3.Infectious Disease Service, Massachusetts Eye and Ear InfirmaryHarvard Medical SchoolBostonUSA
  4. 4.Center for Infectious Disease Research, Diagnostics and ScreeningNational Institute for Public Health and the Environment (RIVM)BilthovenThe Netherlands

Personalised recommendations